Brief: KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals

03/09/2024 11:57

Sept 3 (Reuters) - Kalvista Pharmaceuticals Inc
 KALV.O :
    * KALVISTA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION
FOR
SEBETRALSTAT FOR ORAL ON-DEMAND TREATMENT OF HEREDITARY
ANGIOEDEMA
    * KALVISTA PHARMACEUTICALS INC - FDA PDUFA GOAL DATE OF JUNE
17,
2025
    * KALVISTA PHARMACEUTICALS INC - FDA IS NOT CURRENTLY
PLANNING TO
HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION
    * KALVISTA PHARMACEUTICALS INC -EXPECTS TO FILE FOR APPROVAL
IN
UK, JAPAN, AND OTHER COUNTRIES LATER IN 2024

Source text for Eikon:  ID:nBw9KQTQPa 
Further company coverage:  KALV.O 

 ((Reuters.Briefs@thomsonreuters.com;))